Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00980031 · ClinicalTrials.gov registry record · NA
Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension
A NA study, sponsored by Creighton University.
- Terminated
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT00980031 is a NA study that was terminated before completion, run by Creighton University. The registered enrollment target is 20 participants.
The verdict
NCT00980031, a NA study, was terminated before completion, sponsored by Creighton University.
- TERMINATED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
The goal of this project is to investigate the effects that the addition of aldosterone blockade with eplerenone will have on the progression of diastolic dysfunction in patients with controlled essential hypertension.
Interventions
- DRUG Eplerenone
- DRUG Lactose Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-04 |
| Est. Completion | 2011-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00980031
The ClinicalTrials.gov registry entry for NCT00980031 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Creighton University, which has 98 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Eplerenone is the first listed.
NCT00980031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00980031 about?
NCT00980031 is a clinical study titled "Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension". The goal of this project is to investigate the effects that the addition of aldosterone blockade with eplerenone will have on the progression of diastolic dysfunction in patients with controlled essential hypertension.
What is the current status of trial NCT00980031?
This trial is currently terminated. It is a NA study. The enrollment target is 20 participants. The study started on 2007-04. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00980031?
The interventions under investigation include: Eplerenone (DRUG), Lactose Tablet (DRUG).
Who is sponsoring clinical trial NCT00980031?
This trial is sponsored by Creighton University, which has 98 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.